Pharma major plummets over 10% after third trial disappointment in a week

Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.

CNBC • 3 hours ago

Novartis Says Neuromuscular Drug Candidate Misses Goal in Late-Stage Trial

The drug candidate was one of three therapies the Swiss pharmaceutical company added to its pipeline through its $12 billion acquisition of Avidity Biosciences.

WSJ • 5 hours ago

Novartis announces trial setback on del-desiran drug

Swiss drugmaker Novartis on Tuesday said a late-stage study assessing drug ​del-desiran's impact on myotonic dystrophy, a ‌form of muscle wasting, had not met its target on a key metric, but reaffirmed ​its sales guidance through 2030.

Reuters • 5 hours ago

Novartis stock falls 10% after second drug setback in a week; analyst cuts PT

Novartis shares fell sharply on Tuesday after the Swiss drugmaker said its experimental treatment for myotonic dystrophy failed in a late-stage clinical trial, marking another setback for a pipeline that investors had been counting on to drive future growth. The stock fell about 10% following the announcement and has now lost more than 14% over the past five trading sessions.

Invezz • 2 hours ago

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

CNBC • 6 hours ago

Novartis shares down as failed cholesterol drug study increases pipeline pressure

Shares of Novartis fell 3.3% on Monday morning after its ​cholesterol drug failed in a ‌closely watched study, casting fresh doubt on the therapeutic approach and ​raising the stakes for the ​Swiss drugmaker's upcoming data for ⁠a gene therapy.

Reuters • Sep 7, 2026

Novartis Shares Fall After Heart Drug Misses Target in Late-Stage Trial

The company said the late-stage study for its pelacarsen drug missed its primary objective of reducing the risk of cardiovascular events like death, heart attack and stroke compared with placebo.

WSJ • Sep 7, 2026

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.

Zacks Investment Research • 19 hours ago

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.

Zacks Investment Research • 18 hours ago

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

In a consequential week for Novartis, the Swiss drug maker released results for two of three trials that Wall Street has watched for in the second half of the year.

Barrons • Sep 5, 2026